BOXED WARNING
KADIAN
®
contains morphine sulfate, an opioid
agonist and a Schedule II controlled substance, with an abuse liability similar
to other opioid analgesics. KADIAN
®
can be abused in a manner similar to
other opioid agonists, legal or illicit. This should be considered when
prescribing or dispensing KADIAN
®
in situations where the physician or
pharmacist is concerned about an increased risk of misuse, abuse or
diversion.
KADIAN
®
capsules are an extended-release oral
formulation of morphine sulfate indicated for the management of moderate to
severe pain when a continuous, around-the-clock opioid analgesic is needed for
an extended period of time.
KADIAN® Capsules are NOT for use as a prn analgesic.
KADIAN
®
100 mg and 200 mg Capsules ARE FOR
USE IN OPIOID-TOLERANT PATIENTS ONLY. Ingestion of these capsules or of the
pellets within the capsules may cause fatal respiratory depression when
administered to patients not already tolerant to high doses of opioids.
KADIAN
®
CAPSULES ARE TO BE SWALLOWED WHOLE OR THE CONTENTS OF THE CAPSULES SPRINKLED ON
APPLE SAUCE. THE PELLETS IN THE CAPSULES ARE NOT TO BE CHEWED, CRUSHED, OR
DISSOLVED DUE TO THE RISK OF RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL
DOSE OF MORPHINE.
|
|
KADIAN SUMMARY
KADIAN® (morphine sulfate) capsules are an
opioid analgesic supplied in 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg, 100 mg,
and 200 mg strengths for oral administration.
KADIAN® Capsules are an extended-release
oral formulation of morphine sulfate indicated for the management of moderate to
severe pain when a continuous, around-the-clock opioid analgesic is needed for
an extended period of time (see CLINICAL PHARMACOLOGY).
KADIAN
®
Capsules are NOT intended for use as
a prn analgesic.
KADIAN® is not indicated for pain in the immediate
postoperative period (the first 12-24 hours following surgery), or if the pain
is mild or not expected to persist for an extended period of time. KADIAN® is only indicated for postoperative use if the patient is
already receiving the drug prior to surgery or if the postoperative pain is
expected to be moderate to severe and persist for an extended period of time.
Physicians should individualize treatment, moving from parenteral to oral
analgesics as appropriate. (See American Pain Society guidelines.)
|
|
NEWS HIGHLIGHTSMedia Articles Related to Kadian (Morphine)
The Opioid Crisis and Need for Compassion in Pain Management Source: Medscape Anesthesiology Headlines [2017.09.28] In this commentary, the author expresses concern that the response to the public health crisis of opioid addiction is creating a growing crisis of inadequate pain management. American Journal of Public Health
CVS to Restrict Opioid Painkiller Prescription Amounts Source: MedicineNet Drug Abuse Specialty [2017.09.25] Title: CVS to Restrict Opioid Painkiller Prescription Amounts Category: Health News Created: 9/22/2017 12:00:00 AM Last Editorial Review: 9/25/2017 12:00:00 AM
Stomach Pain Quiz: Nausea & Other Causes Source: MedicineNet Anal Fissure Specialty [2017.09.19] Title: Stomach Pain Quiz: Nausea & Other Causes Category: MedicineNet Quiz Created: 1/20/2011 12:00:00 AM Last Editorial Review: 9/19/2017 5:59:56 PM
Back Pain Quiz: Test Your Back Pain IQ Source: MedicineNet Ankylosing Spondylitis Specialty [2017.09.19] Title: Back Pain Quiz: Test Your Back Pain IQ Category: MedicineNet Quiz Created: 6/16/2011 3:41:00 PM Last Editorial Review: 9/19/2017 6:39:04 PM
Pain Quiz: Test Your IQ of Pain Source: MedicineNet Constipation Specialty [2017.09.19] Title: Pain Quiz: Test Your IQ of Pain Category: MedicineNet Quiz Created: 7/14/2011 3:53:00 PM Last Editorial Review: 9/19/2017 6:41:41 PM
Published Studies Related to Kadian (Morphine)
Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in
Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a
randomized controlled trial. [2015] BACKGROUND: Ticagrelor is an oral platelet P2Y12 receptor antagonist which is
recommended for patients suffering from myocardial infarction, both with and
without persistent ST segment elevation... DISCUSSION: This study is expected to provide essential evidence-based data on
the impact of morphine on the absorption of ticagrelor in patients with
myocardial infarction as well as to shed some light on the suspected connection
between morphine use and antiplatelet activity of ticagrelor in the same group of
patients.
Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses
determined from oral morphine rescue doses in the treatment of breakthrough
cancer pain. [2015] evaluate the efficacy and safety of sublingual fentanyl tablet... CONCLUSIONS: Patients treated with strong opioid analgesics at fixed intervals
Evaluation of a single-dose, extended-release epidural morphine formulation for
pain control after lumbar spine surgery. [2014] DepoDur, an extended-release epidural morphine, has been used effectively for
postoperative pain control following many orthopaedic and general surgery
procedures and has provided prolonged analgesia when compared with Duramorph. The
goal of this article was to compare the safety and analgesic efficacy of DepoDur
versus Duramorph after lumbar spine surgery...
Morphine decreases clopidogrel concentrations and effects: a randomized,
double-blind, placebo-controlled trial. [2014] effects on platelets... CONCLUSIONS: Morphine delays clopidogrel absorption, decreases plasma levels of
Transversus abdominis plane block versus perioperative intravenous lidocaine
versus patient-controlled intravenous morphine for postoperative pain control
after laparoscopic colorectal surgery: study protocol for a prospective,
randomized, double-blind controlled clinical trial. [2014] BACKGROUND: Despite the laparoscopic approach becoming the standard in colorectal
surgery, postoperative pain management for minimally invasive surgery is still
mainly based on strategies that have been established for open surgical
procedures... DISCUSSION: Recognizing the importance of a multimodal approach for perioperative
pain management, we aim to investigate whether a transversus abdominis plane
block delivers superior pain control in comparison to perioperative intravenous
lidocaine and patient-controlled intravenous analgesia with morphine alone.
Clinical Trials Related to Kadian (Morphine)
Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water [Completed]
The objective of this study was to compare the single-dose relative bioavailability of
Alpharma Branded Products Division Inc. (KADIAN) 100 mg morphine sulfate extended-release
capsules when dosed with alcohol under fasting and fed conditions compared to water.
In addition, the pharmacokinetics of an immediate release solution following a 20 mg dose
was assessed for informational purposes and for possible modeling.
Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions [Completed]
The objective of this single-dose, open-label, randomized, two-period crossover study was to
compare the rate of absorption and oral bioavailability of a test formulation of morphine
sulfate 200 mg sustained-release capsules manufactured by Alpharma Branded Products Division
Inc. to an equivalent oral dose of the commercially available reference product, KADIAN 2 x
100 mg capsules manufactured by Alpharma Branded Products Division Inc. when administered
under fed conditions.
Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fasting Conditions [Completed]
The objective of this single-dose, open-label, randomized, two-period crossover study was to
compare the rate of absorption and oral bioavailability of a test formulation of morphine
sulfate 200 mg sustained-release capsules manufactured by Alpharma Branded Products Division
Inc. to an equivalent oral dose of the commercially available reference product, KADIAN 2 x
100 mg capsules manufactured by Alpharma Branded Products Division Inc. when administered
after a 10-hour overnight fast.
Comparison of One Morphine Sulfate Sustained-Release 200 mg Capsule With Two 100 mg KADIAN Capsules on Applesauce [Completed]
The objective of this single-dose, open-label, randomized, two-period crossover study was to
compare the rate of absorption and oral bioavailability of a test formulation of morphine
sulfate 200 mg sustained-release capsules manufactured by Alpharma Branded Products Division
Inc. to an equivalent oral dose of the commercially available reference product, KADIAN 2 x
100 mg capsules manufactured by Alpharma Branded Products Division Inc. when administered as
a sprinkle on applesauce after a 10-hour overnight fast.
Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions [Completed]
The objective of this single-dose, open-label, randomized, two-treatment, two-period
crossover study was to compare the relative bioavailability of a test formulation of KADIAN
(2 x 10 mg) capsules manufactured by Alpharma Inc. to an equivalent oral dose of the
commercially available reference product, KADIAN (1 x 20 mg)capsules manufactured by
Alpharma Branded Products Inc. following an overnight fast of at least 10 hours.
Reports of Suspected Kadian (Morphine) Side Effects
Toxicity TO Various Agents (43),
Unresponsive TO Stimuli (40),
Completed Suicide (14),
Hypotension (14),
Pulmonary Oedema (11),
Accidental Death (10),
Intentional Drug Misuse (10),
Drug Abuse (8),
Cardio-Respiratory Arrest (8),
Brain Oedema (8), more >>
|
|
Page last updated: 2017-09-28
|